New combo aims to control mantle cell lymphoma without chemo

NCT ID NCT02682641

Ongoing Disease control Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial is testing a combination of two drugs—ibrutinib and rituximab—in 50 people with untreated, slow-growing mantle cell lymphoma. The goal is to see if this drug pair can shrink or eliminate the cancer and keep it from progressing. Researchers will also study the tumor's genetic makeup to better understand who responds best.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ibrutinib (Imbruvica) and rituximab (Rituxan)
What this could lead to: If successful, this combination could offer a highly effective first treatment for people with slow-growing mantle cell lymphoma, potentially leading to long-term disease control without immediate chemotherapy.
What could go wrong: This is a mid-stage trial with only 50 participants, so results may not apply to everyone. The treatment may cause side effects like infections or bleeding, and it is not a cure—patients may need ongoing therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Locations

Hospital Clínic de Barcelona

Barcelona, Barcelona, 08036, Spain
Hospital Clínico de Valencia

Valencia, Valencia, Spain
Hospital Costa del Sol

Marbella, Málaga, Spain
Hospital General Universitario Santa Lucía

Cartagena, Murcia, Spain
Hospital Universitario 12 de Octubre

Madrid, Madrid, 28041, Spain
Hospital Universitario Clinico de Salamanca

Salamanca, Spain
Hospital Universitario Fundación Alcorcón

Alcorcón, Madrid, Spain
Hospital Universitario Mútua Terrassa

Terrassa, Barcelona, Spain
Hospital Universitario Ramon y Cajal

Madrid, Madrid, Spain
Hospital Universitario Vall d'Hebron

Barcelona, Barcelona, Spain
Hospital Universitario Virgen del Rocio

Seville, Sevilla, Spain
Hospital Universitario de Burgos

Burgos, Burgos, Spain
Hospital de la Santa Creu i Sant Pau

Barcelona, Barcelona, Spain
Institut Català d'Oncologia

Barcelona, Barcelona, Spain
MD Anderson Cancer Center

Madrid, Madrid, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.